An absorbent article comprising at least a topsheet layer and a backsheet layer, each layer having a first and a second surface, at least one of the layers has a composition comprising a skin beneficial agent printed on the first surface and an ink composition printed on the second surface, wherein the compositions on the first and the second surfaces respectively may be interchanged.

A microsphere includes a cross-linked hydrophilic substrate, a lipophilic substrate, and a surfactant. The cross-linked hydrophilic substrate includes cross-linked sodium alginate and gelatin. The lipophilic substrate includes iodized oil, C16-C18 alkyl alcohol, and polycaprolactone. The surfactant includes polyoxyethylene stearate. The microsphere is dry or substantially solid. Prior to being used for embolization, the microsphere can be immersed in a drug containing mixture to allow the microsphere to absorb the mixture and expand, thereby loaded with the drug. A method for preparing the microsphere and a method for embolizing tumor in a subject by using the microsphere are also provided.

Various examples are provided for controlled drug release over an extended period of time. In one example, a controlled release system includes a multilayer membrane including a first biocompatible nanofiber layer; a microbead layer disposed on the first biocompatible nanofiber layer, the microbeads comprising a releasable agent; and a second biocompatible nanofiber layer disposed over the microbead layer. The first and second biocompatible nanofiber layers support the microbead layer and provide a diffusion barrier that can control a release profile of the releasable agent.

A therapeutic agent which inhibits cytokines and/or inflammatory mediators for use in the treatment of a patient affected by inflammation associated with atherosclerosis and/or a thrombotic state, wherein the treatment includes the local administration of the therapeutic agent in a blood vessel by an intravascular medical device directly at the level of an atherosclerotic plaque, and/or a site of inflammation, and/or a site of a thrombotic phenomenon.

A hydrogel material for the treatment of stroke or other brain injury includes a collection of hyaluronic acid-based microgel particles comprising one or more network crosslinker components, wherein the hyaluronic acid-based microgel particles, when exposed to an endogenous annealing agent (e.g., Factor XIIIa), links the hyaluronic acid-based microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. The hydrogel material may be injected into a stroke cavity and was shown to promote brain tissue repair by promoting the recruitment of neural stem cells to the injured site and reducing the post-stroke inflammatory response.

The absorbent article comprises at least a topsheet layer and a backsheet layer, each layer having a body facing surface and a garment facing surface, and longitudinal and transversal edges, the article having a longitudinal front portion, a longitudinal back portion and a crotch portion located between the front and the back portion. The article comprises a first and a second zone of microencapsulated phase change material on a surface of a layer of the article. The first and second zones are selected form zones having different microencapsulated phase change materials, different concentrations of a microencapsulated phase change material or comprise microencapsulated phase change material having different phase change temperature intervals.

A differential tissue-engineered nerve including motor-like nerves and sensory-like nerves. The motor-like nerve and the sensory-like nerve respectively includes a motor-like nerve outer tube and a motor-like nerve fiber in the outer tube as well as a sensory-like nerve outer tube and a sensory-like nerve fiber in the outer tube. Schwann cells and/or fibroblasts derived from motor nerves and sensory nerves are respectively contained in surfaces or pores of the motor-like and sensory-like nerve outer tubes. Transsynaptic signal molecules Neuroligin-1 and Neuroligin-2 are contained in surfaces or pores of the motor-like and sensory-like nerve fibers. Neuroligin-1 is selectively used to specifically promote synaptic remodeling of motor neurons, while Neuroligin-2 is selectively used to specifically promote synaptic remodeling of sensory neurons, so that repair efficiency of motor nerve cells and sensory nerve cells is improved.

The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.

An intraocular lenses having a plurality of drug-containing microspheres attached to the intraocular lens. The intraocular lenses can be used for patients undergoing cataract surgery and reduces the need for recurrent surgery, follow-up treatment or postoperative eye-drops. Also provides a method for manufacturing such an intraocular lens and the use of an intraocular lens in the treatment of cataract.

Luminal grafts and methods of making and using the same. An exemplary luminal graft of the present disclosure is configured as a generally tubular element configured for nerve cells to grow therethrough and comprises at least one sheet of biological tissue having elastin fibers and collagen fibers, with the elastin fibers being a dominant component thereof; and a plurality of microchannels formed on a surface of the at least one sheet of biological tissue, each of the microchannels extending longitudinally between a first end and a second end of the at least one sheet of biological tissue and configured to provide intraluminal structural guidance to nerve cells proliferating therethrough.